RxDoctor Payments Data

Peng Fan

North Hollywood, CANPI 1104801463

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $192,704 of the $231,581 with a category attached, or 83.2%. 11 manufacturers reported payments, led by Amgen at 49.2% of the total. Reporting peaked in 2019 at $184,396 and has fallen 96.1% since, to $7,277 in 2024.

$231,581in general payments, 2019–2025

Across 375 payments — averaging $617.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$114K
  • Novartis$36K
  • Sanofi$22K
  • Pfizer$21K
  • AbbVie$18K
  • Radius Health, Inc.$16K
  • plus $5K from 5 others

What the payments were for

  • Speaking & faculty fees$192,70483%
  • Travel & lodging$30,38313%
  • Food & beverage$8,3954%
  • Education$990%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen171$113,901
Novartis71$36,027
Sanofi29$22,329
Pfizer30$20,865
AbbVie33$17,572
Radius Health, Inc.18$15,824
Regeneron Healthcare Solutions, Inc.15$4,812
Sanofi-aventis U.S. LLC2$137
GSK4$75
Johnson & Johnson1$19
Boston Scientific1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →